x
Filter:
Filters applied
- Melanoma
- TCGARemove TCGA filter
- MITFRemove MITF filter
- microphthalmia-associated transcription factorRemove microphthalmia-associated transcription factor filter
Melanoma
2 Results
- Letter to the EditorOpen Access
Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities
Journal of Investigative DermatologyVol. 136Issue 12p2502–2505Published online: June 23, 2016- Martin Lauss
- Jeremie Nsengimana
- Johan Staaf
- Julia Newton-Bishop
- Göran Jönsson
Cited in Scopus: 20Identification of recurrent mutation in the BRAF oncogene in melanoma has led to the development of highly selective kinase inhibitors (Larkin et al., 2014). Although dramatic treatment responses are initially observed, responses are rarely durable. The mutational classification based on BRAF, NRAS, and NF1 mutations that has been established, however, is nonoverlapping with classification derived from gene expression profiling (The Cancer Genome Atlas Network [TCGA], 2015; Jönsson et al., 2010). - Original Article Melanocytes/MelanomaOpen Archive
Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 Cascade
Journal of Investigative DermatologyVol. 136Issue 6p1229–1237Published online: March 8, 2016- Florian Rambow
- Audrey Bechadergue
- Flavie Luciani
- Gwendoline Gros
- Melanie Domingues
- Jacky Bonaventure
- and others
Cited in Scopus: 21Melanoma progression from a primary lesion to a distant metastasis is a complex process associated with genetic alterations, epigenetic modifications, and phenotypic switches. Elucidation of these phenomena may indicate how to interfere with this fatal disease. The role of microRNAs as key negative regulators of gene expression, controlling all cellular processes including cell migration and invasion, is now being recognized. Here, we used in silico analysis of microRNA expression profiles of primary and metastatic melanomas and functional experiments to show that microRNA-125b (miR-125b) is a determinant candidate of melanoma progression: (i) miR-125b is more strongly expressed in aggressive metastatic than primary melanomas, (ii) there is an inverse correlation between the amount of miR-125b and overall patient survival, (iii) invasion/migration potentials in vitro are inversely correlated with the amount of miR-125b in a series of human melanoma cell lines, and (iv) inhibition of miR-125b reduces migratory and invasive potentials without affecting cell proliferation in vitro.